Our Mission: Healthy Hearing Available to All.
We are a precision genetic medicine company focused on developing gene therapies with the potential to restore, improve and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss.
We are a precision genetic medicine company focused on developing gene therapies with the potential to restore, improve and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $162.5M
Founded date: 2016
Investors 6
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | 5AM Ventur... | 5amventure... |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | NFLS - Piv... | pivotalbio... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 06.04.2020 | Series B | $105M | - |
| 13.08.2018 | Series A | $50M | - |
| 04.12.2017 | Seed | $7.5M | New Enterp... |
Mentions in press and media 27
| Date | Title | Description |
| 31.01.2026 | Eli Lilly Forges $1.12 Billion Gene Editing Alliance for Hearing Loss | Eli Lilly sealed a $1.12 billion deal with Germany's Seamless Therapeutics. This major collaboration aims to develop advanced gene editing treatments for hearing loss. Lilly gains access to Seamless's precision recombinase platform. The tec... |
| 28.01.2026 | Eli Lilly заключила сделку до $1,12 млрд со стартапом Seamless Therapeutics | Об этом в среду сообщила немецкая стартап-компания. Партнерство направлено на разработку и коммерциализацию методов лечения потери слуха с использованием платформы генного редактирования Seamless. Сделка предоставит Lilly доступ к собственн... |
| 07.02.2022 | Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions at the Association for Research in Otolaryngolog... | - Data from two nonclinical studies evaluating protein expression and tolerability support future clinical development of AK-antiVEGF for the treatment of vestibular schwannoma - AAVAnc80 and a supporting cell selective promoter can drive w... |
| 06.04.2020 | Weekly Refresh: Akouos Raised $105M, Demo Days Go Virtual, and More | Photo: Shutterstock Akouos gained $105M. The genetic medicine company is working on gene therapies related to preserving and restoring hearing. Pivotal bioVenture Partners led the Series B. [FinSMEs] JobGet launched hiring initiative. It of... |
| 31.03.2020 | Akouos Raises $105M in Series B Financing | Akouos, Inc., a Boston, Mass.-based precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing, raised $105m in Series B financing. The round was led by Pivotal bioVenture Partners, with p... |
| 05.03.2020 | Precision Genetic Medicine Company Akouos Secures $105 Million In Funding | Akouos, a precision genetic medicine company that is developing potential gene therapies to restore, improve, or preserve hearing, announced it raised $105 million Akouos — a precision genetic medicine company that is developing potential g... |
| 03.03.2020 | Akouos Closes $105 Million Series B Financing | BOSTON--(BUSINESS WIRE)--Akouos, Inc. a precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing, today announced it has raised $105 million in an oversubscribed Series B financing. The ... |
| 03.03.2020 | Top tech startup news for today, Tuesday, March 3, 2020: Amazon, Twitter, Akouos, Robinhood | Good morning! Below are the top tech startups news for today, Tuesday, March 3, 2020. Amazon launches same-day delivery in four states. Amazon is now offering same-day delivery to customers in Philadelphia, Pennsylvania; Phoenix, Arizona; ... |
| 03.03.2020 | Akouos Closes $105 Million Series B Financing | - |
| 03.03.2020 | Akouos Closes $105 Million Series B Financing | - |
Show more